Возможности терапии климактерических симптомов с помощью препаратов мелатонина
- Авторы: Кузнецова И.В.1, Бурчаков Д.И.2
-
Учреждения:
- ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
- ФГБУ Эндокринологический научный центр Минздрава России
- Выпуск: Том 17, № 5 (2015)
- Страницы: 44-48
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2079-5831/article/view/28481
- ID: 28481
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Ирина Всеволодовна Кузнецова
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава Россиид-р мед. наук, проф., глав. науч. сотр. научно-исследовательского отд. женского здоровья Научно-исследовательского центра ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
Денис Игоревич Бурчаков
ФГБУ Эндокринологический научный центр Минздрава России
Email: dr.burchakov@yandex.ru
врач-эндокринолог, сомнолог ФГБУ ЭНЦ 117036, Россия, Москва, ул. Дмитрия Ульянова, д. 11
Список литературы
- Клинические рекомендации. Акушерство и гинекология. Вып. 2. Под ред. В.И.Кулакова. М.: ГЭОТАР-Медиа, 2008.
- Genazzani A.R, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. Climacteric 2007; 10 (2): 88-96.
- Nelson H.D, Haney E, Humphrey L et al. Management of menopause - related symptoms. Evid Rep Technol Assess (Summ) 2005; 120: 1-6.
- Сметник В.П., Ильина Л.М. Роль половых гормонов в развитии метаболических расстройств у женщин в пери - и ранней постменопаузе. Климактерий. 2009; 1: 8-13.
- North American Menopause Society. Treatment of menopause - associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004; 11: 11-33.
- Col N.F, Guthrie J.R, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle - aged women: a longitudinal study. Menopause 2009; 16:453-7.
- Politi M.C, Schleinitz M.D, Col N.F. Revisting the duration of vasomotor symptoms of menopause: a meta - analysis. J Gen Intern Med 2008; 23: 1507-13.
- Freeman E.W, Sammel M.D, Lin H et al. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011; 11 (5):1095-104.
- Loprinzi C.L, Barton D.L. On hot flash mechanism, measurement, and treatment. Menopause 2009; 16: 621-3.
- Freedman R. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005; 23 (2): 117-25.
- Skurnick J.H, Weiss G, Goldsmith L.T et al. Longitudinal changes in hypothalamic and ovarian function in perimenopausal women with anovulatory cycles: relationship with vasomotor symptoms. Fertil Steril 2009; 91 (4):1127-34.
- Rapkin A.J. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007; 196: 97-106.
- Freedman R.R, Benton M.D, Genic R.J, Graydon F.X. Cortical activation during menopausal hot flashes. Fertil Steril 2006; 85: 674-8.
- Freeman E.W, Sammel M.D, Lin H et al. The role of anxiety and hormonal changes in menopausa hot flashes. Menopause 2005; 12: 258-66.
- Juang K.D, Wang S.J, Lu S.R et al. Hot flashes are associated with psychological symptoms of anxiety and depression in peri - and post - but not premenopausal women. Maturitas 2005; 52: 119-26.
- Hodis H.N, Mack W.J. Postmenopausal hormone therapy in clinical perspective. Menopause, 2007; 14 (5): 944-57.
- Sturdee D.W et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011; 14: 302-20.
- Gompel A, Rozenberg S, Barlow D.H. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 2008; 61: 227-32.
- Hill D.A, Hill S.R. Counseling patients about hormone therapy and alternatives for menopausal symptoms. Am Fam Physician 2010; 82: 801-7.
- Tsai S.A, Stefanick M.L, Stafford R.S. Trends in menopausal hormone therapy use of US office - based physicians, 2000-2009. Menopause 2011; 18: 385-92.
- Kronenberg F, Cushman L.F, Wade C.M et al. Race/ethnicity and women`s use of complementary and alternative medicine in the United States: results of national survey. Am J Public Health 2006; 96: 1236-42.
- Reddy S.Y, Warner H, Gutusso T et al. Gabapentin, estrogen and placebo for treating hot flashes. Obstet Gynecol 2006; 108: 41-8.
- Fonken L.K, Randy J.N. The effects of light at night on circadian clocks and metabolism. Endocr Rev 2014; 35 (4): 648-70.
- Tamura H, Takasaki A, Taketani T et al. Melatonin and female reproduction. J Bstet Gynaecol Res 2014; 40: 1-11.
- Hill S, Belancio V, Dauchy R et al. Melatonin: an Inhibitor of Breast Cancer. Endocr Relat Cancer 2015; 22: 183-204.
- Tsutsui K, Ubuka T, Bentley G et al. Review: regulatory mechanisms of gonadotropin - inhibitory hormone (GnIH) synthesis and release in photoperiodic animals. Front Neurosci 2013; 7: 60.
- Toffol E, Kallenen N, Haukka J et al. Melatonin in perimenopausal and postmenopausal Women: associations with mood, sleep, climacteric symptoms, and quality of life. Menopause 2014; 21 (5): 493-500.
- Greene J. Constructing a standard climacteric scale. Maturitas 2008; 61: 78-84.
- Nunes D, Mota R, Machado M. Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease. Braz J Med Biol Res 2008; 41: 926-31.
- Bruyneel M. Sleep disturbances in menopausal women: aetilogy and practical aspects. Maturitas 2015; 81: 406-9.
- Parandavar N, Abdali K, Keshtgar S. The effect of melatonin on climacteric symptoms in menopausal women; a double - blind, randomized controlled, clinical trial. Iran J Public Health 2014; 43: 1405-16.
Дополнительные файлы
